• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Obstetrics

Relative survival for ovarian cancer improved over three decades

byMaren ShapiroandLeah Hawkins Bressler, MD, MPH
May 10, 2015
in Obstetrics, Oncology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. Survival for all stages of ovarian cancer improved significantly from 1975 to 2011 even after accounting for general advances in medical care.

2. Compared to 1975, women diagnosed with ovarian cancer in 2006 were roughly 50 percent less likely to die from their cancer.

Evidence Rating Level: 2 (Good)

Study Rundown: In 2015, approximately 21 290 American women will receive a new diagnosis of ovarian cancer and 14 180 will die from the disease. But a cancer that once was seen as a death sentence is now treatable. Thanks to tremendous advancements in scientific research, we now understand the value of debulking surgeries to remove tumor in advanced stage disease, the benefit of platinum chemotherapeutic agents and novel methods of medication delivery, such as intraperitoneal chemotherapy. Despite these advances, determining whether advances in treatment translate to population-level improvements in survival is difficult because improvements in medical care have also translated to prolonged life expectancy overall. In this study, researchers attempted to address this challenge by using relative survival—the ratio of survival for cancer patients to the expected survival of a comparable group from the general population.

According to data from a large national cancer database, relative survival for ovarian cancer has improved significantly over the past 3 decades, regardless of tumor stage.  Compared to 1975, women diagnosed with breast cancer in 2006 were roughly 50 percent less likely to die from their cancer. Strengths of this study include the large, nationally representative sample and accounting for advances in general medical care. One significant limitation was that staging criteria have changed over the years so some women may have been misclassified. Future studies that classify survival based on treatment type will further add to our understanding of the impact of advancements in ovarian cancer treatment.

Click to read the study in Obstetrics & Gynecology

Relevant Reading: Improved survival time: what can survival cure models tell us about population-based survival improvements in late-stage colorectal, ovarian, and testicular cancer?

RELATED REPORTS

Intraperitoneal chemotherapy improves advanced ovarian cancer survival [Classics Series]

Ovarian cancer screening does not reduce mortality [Classics Series]

MRI enhances diagnostic certainty of ovarian cancer following indeterminate ultrasound [Classics Series]

In-Depth [retrospective cohort]: Women diagnosed with ovarian cancer from 1975 to 2011               (n = 42 932) were identified in the National Cancer Institute’s Surveillance, Epidemiology, and End Results database. Relative survival was estimated by comparing observed survival after cancer diagnosis with expected survival of a comparable group from the general population; excess mortality was the mortality rate above baseline in the general population. Mortality was compared for different time periods using hazard ratios.

For women with stage I ovarian cancer, excess mortality in 2006 was nearly half that in 1975   (HR = 0.51, 95%CI 0.41-0.63). Reduction in excess mortality remained significant when compared to 1980 and 1985. For women with stage III-IV cancer, excess mortality was lower in 2006 compared with all other years of study (relative to 1975, HR = 0.49, 95%CI 0.44-0.55; relative to 2000, HR = 0.93, 95%CI 0.87-0.99)

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: ovarian cancersurvivorship
Previous Post

Over-the-counter pain relievers not harmful to reproductive function

Next Post

Screening model examines neonatal detection of congenital heart defects

RelatedReports

The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Obstetrics and Gynecology Classics

Intraperitoneal chemotherapy improves advanced ovarian cancer survival [Classics Series]

September 16, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

Ovarian cancer screening does not reduce mortality [Classics Series]

August 12, 2022
The ABCD2 score: Risk of stroke after Transient Ischemic Attack (TIA) [Classics Series]
Radiology Classics

MRI enhances diagnostic certainty of ovarian cancer following indeterminate ultrasound [Classics Series]

August 10, 2022
Lower target oxygen saturation in extremely preterm infants appears safe
Oncology

Apatinib plus pegylated liposomal doxorubicin as an alternative treatment option in platinum-resistant ovarian cancer

July 11, 2022
Next Post
Noninvasive ventilation strategies examined in NICU infants

Screening model examines neonatal detection of congenital heart defects

Study evaluates academic consequences of concussions in youth

Study evaluates academic consequences of concussions in youth

Cardiac biomarkers unnecessarily ordered in emergency departments

Higher mortality among frequent ED users compared to non-frequent users

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Deep intronic FGF14 repeat expansion associated with late-onset cerebella ataxia
  • Plant-based diets may be associated with lower risk of aggressive prostate cancer
  • #VisualAbstract: Adagrasib provides antitumour activity against KRAS G12C mutant metastatic colorectal cancer both as monotherapy and in combination with cetuximab
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options